scott ballin. did i get that right? >> ballin. >> i apologize. >> close enough. >> i was betting on ballin. >> and happy birthday, sir. >> mr. scott ballin is a tobacco and health policy consultant. >> yes. mr. chairman and members of the committee, thank you for the opportunity to be here. i've spent much of my professional career dedicated to working in the public health arena and in particular tobacco and nicotine area. i worked with the heart association for many years, the coalition on smoking and health. i have been around a long time. i also feel the age. i come here today to give you my thoughts on issues being raised in this hearing as well as on related issues and some of those have come up here on what is a very dynamic, emotionally charged, and rapidly changing environment. this includes the broad topic of how all tobacco, nicotine, and other products, should be regulated, including their advertising and marketing. i and many others including the director of the fda center for leave we are in a new era, and

ballin, you are very optimistic men. your document sitting around a table and resolving these things. you know what it took? they all sat across there any different then you in congress raising their hands, swore to tell the truth and then lied. and at that point we return and things began to happen and we began to make progress at that point. i just want to say we don't ask people to raise their hands because you just need to know and we all know that you have to tell the truth because of 18 usc 101. so i heard a couple things here that are not true. i just want to talk about these things. for example, i think mr. healy, you said -- it's true, it's your opinion, this is the greatest invention ever to get people off of the of the cigarettes. you said that spent yes, sender. spent i asked in an is considered a plus in the record an american hard review to review the scientific journal but have you seen the? >> i don't believe i have spent we'll put it in the record unless there's a check and, okay. and here's the deal. it

they pivoted but look at the idea of ballin' shade over the last 20 years. nd relate that to the e.p.s. growth. >> a shout out to tony sock november. he is a neutral. >> we're going to continue this discussion on productivity and innovation later today. who's winning the battle for the most innovative companies. we will discuss right here on "surveillance." >> coming up on bloomberg television, an interview that you will want to tune in for. former federal reserve chairman alan greenspan will be "in the loop" joining betty and tom. they'll be discussing the g.d.p. report and jobs. the feds rolling providing liquidity. >> and i want to turn about being measured. can this fed afford to be measured? >> i would love for you to get asking on fed chairman about markets. he was the one who made the exuberance -- >> good question. i like that. brilliant. >> >> all right. this is "bloomberg surveillance." i'm scarlet fu with tom keene and adam johnson. let's get you some company news from the files of bloomberg west. twitter says soccer fans helped its second quarter

scott ballin. he is a tobacco and health policy consultant. >> mr. chairman and members of the committee, thank you for the opportunity to be here. i spent much of my professional career dedicated to working in the public health areenave. worked for the heart association for many years and i have been around a long time so i also feel the age. i come here today to give you my thoughts on issues being raised and some of those have come up here on what is a dynamic and rapidly commanging environment. on how all nicotine production should be regular i lated. i and many others including the direct for of the f.d.a. center of toib products are in a new era. looking to develop a more comprehensive rationale and workable approach. this next stage could be as significant as our requiring of f.d.a. oversight of tobacco a few years ago. a growing spectrum of products ncluding e-cigarettes that eliminate the combustible cigarette. it entails accepting and using the continue you'll risk, that would regulate cigarettes their intended uses. all tobacco products we

ballin. there's a lot of discussion of harm to e-cigarettes. you degree with the center of tobacco products who has said there is a continuing risk. you said that those are on the uses. can you elaborate on how we can find the appropriate balance or e-cigarettes and what the key players can do to further that dialogue and scientific research? >> i think that what i'm hearing around this table is actually a common direction of what needs to be done. needs to be more research. no question about it. kneads to be -- needs to be done by f.d.a. and universities and academics. industry has a responsibility also. there was a statement made by someone earlier that there has to be accountability of this industry. as the agency continues to regulate the products and anyone wants to file anything, they are going to have to have the proof to back up. the agency to prove the product or allow a claim or anything else. we need to head that in that direction quickly. i think we need a aggressive monitoring surveillance system. we talked about that many, many ye